### Please fax both pages of completed form to your team at 808.650.6487.

To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to <u>MyAccredoPatients.com</u> to log in or get started.

## Prescription & Enrollment Form Tezspire<sup>™</sup> (tezepelumab-ekko)



Four simple steps to submit your referral.

Detient	Information
Patient	Information
 - i ationt	mornation

/	$\frown$	D
(		1
		а

Please provide copies of front and back of all medical and prescription insurance cards.

New patient Current patie	nt		
Patient's first name		Last name	Middle initial
Sex at birth: Male Female	Preferred pronouns	Last 4 digits of SSN	Date of birth
Street address			Apt #
City		State	Zip
Home phone	Cell phone	Email address	
Parent/guardian (if applicable)			
		Email address	
Alternate caregiver/contact			
Home phone	Cell phone	Email address	
OK to leave message with alter	nate caregiver/contact		

Patient's primary language: English Other If other, please specify \_

# **2** Prescriber Information

All fields must be completed to expedite prescription fulfillment.

Date	Time		Date medication need	led	
Office/clinic/institution n	ame				
Prescriber info: Prescribe	er's first name		Last n	ame	
Prescriber's title		If NF	or PA, under directio	n of Dr	
Office phone	Fax		_ NPI #	License #	
Office contact and title _			Office c	ontact email	
Office street address				Su	ite #
City		State			Zip
Infusion location: Patie	ent's home Prescriber's offic	e Infusion site	If infusion site, com	plete information below of	lotted line:
Infusion info: Infusion sit	te name		Clinic/hospital af	filiation	
Site street address				Suit	e #
City		State			Zip
Infusion site contact	P	hone	Fax	Email	
3 Clinical I	nformation				
ICD-10 code (REQUIRED Other	): 45.50 Severe persistent			ere persistent asthma wit	
	g allergies				
Prior anaphylactic reaction	on: Yes (Reason/date				) No
Concurrent meds					
Concomitant therapies:	Short-acting beta agonist	Long-acting bet	a agonist Antihista	mines Decongestants	s Immunotherapy

Inhaled corticost	eroid Leukotriene mo	difiers Oral	steroids Nasa	I steroids Other _			
Lab results: Hist	ory of positive skin OR R	AST test to a p	perennial aeroaller	gen			
Pre-treatment serun	n IgE level	_IU per mL Te	est date	Pre-treatmen	t serum	eosinophils	cells/mcL
and/or sputum eosir	nophils	Date	Pat	ient wt	kg	Date wt obtained	

 MD Specialty (required):
 Allergist
 Pulmonologist
 ENT
 Primary care
 Pediatrician
 Other
 \_\_\_\_\_\_

 Prescription type:
 Naïve/new start
 Restart
 Continued therapy

#### Prescription & Enrollment Form: Tezspire<sup>™</sup> (tezepelumab-ekko)

Patient's first name	Last name	Middle initial Date of birth	
Prescriber's first name	Last name	Phono	
Prescriber's first fiame	Last name	Phone	

# **4** Prescribing Information

Medication	Strength/Formulation	Directions	Quantity/Refills
Tezspire™ (tezepelumab)	210mg/1.91mL prefilled syringe	Inject 210mg under the skin every 4 weeks. Note: To be administered by a health care provider in a healthcare setting.	1-month supply 3-month supply Other:
	210mg/1.91mL prefilled pen	Inject 210mg under the skin every 4 weeks. Note: Can be shipped to patient or healthcare provider.	Refills

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

### Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN HERE				
	Date	Dispense as written	Date	Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient, fit is information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. © 2023 Accredo Health Group, Inc. I An Express Scripts Company. All rights reserved. AST-00005-H-050223 CRP2404\_8354